Texas-based contract manufacturing organization (CMO) VGXI has completion initial tech transfer milestones as part of its partnership agreement for the production of RNA therapeutics with the Houston Methodist Research Institute (HMRI).
 
Under a license agreement with HMRI for development of clinical grade RNA manufacturing services, VGXI has completed all of the partnership’s Phase I initiatives and anticipates Phase II will conclude by 4Q 2019. The plan includes establishment and operation of a pilot RNA production plant at the VGXI facility in parallel with method optimization to prepare for scale-up and clinical grade service offerings.
 
VGXI is recognized among the DNA vaccine and gene therapy industries for its products and services. The addition of RNA production and testing in 2019 will provide a complement to this service line by leveraging technical knowledge and proven processes for production of nucleic acid-based pharmaceuticals.